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CONTINUED MEDICAL EDUCATION
Pain in photodynamic therapy: mechanism of action 
and management strategies *
Dor na terapia fotodinâmica: mecanismo de ação e estratégias de manejo
Yuri Nogueira Chaves1 Luis Antônio Torezan2
Ane Beatriz Mautari Niwa3 José Antônio Sanches Junior4
Ciro Festa Neto5
Abstract: Photodynamic therapy involves administration of a photosensitizing drug and its subsequent
activation by irradiation with a light source at wavelengths matching the absorption spectrum of the
photosensitizer. In many countries around the world, topical photodynamic therapy has been appro-
ved for treatment of cutaneous oncologic conditions such as actinic keratosis, Bowen's disease, and
superficial basal cell carcinoma. Multicenter, randomized, controlled studies have confirmed its effica-
cy and superior cosmetic outcomes compared to conventional therapies. Nevertheless, this therapeu-
tic method presents some adverse effects, such as erythema, edema, pigmentation, pustules, and pain.
There is no doubt that pain is the most severe of the adverse effects, being sometimes responsible for
definitive treatment interruption. The pain mechanism has not yet been fully understood, which makes
complete pain control a challenge to be conquered. In spite of that, this literature review presents
some useful pain management strategies as well as the most important pain-related factors in photo-
dynamic therapy. 
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Resumo: A terapia fotodinâmica consiste na administração de uma droga fotossensibilizante e sua sub-
seqüente irradiação com uma fonte de luz de espectro correspondente ao do seu fotossensibilizador.
Em diversos países do mundo, a terapia fotodinâmica tópica é aprovada para o tratamento de condi-
ções oncológicas cutâneas como queratoses actínicas, doença de Bowen e carcinoma basocelular
superficial. Estudos multicêntricos controlados e randomizados confirmam sua eficácia e seus resulta-
dos cosméticos superiores em relação às terapias convencionais. No entanto, existem alguns efeitos
adversos inerentes a esse método terapêutico, como eritema, edema, pigmentação, pústulas e dor.
Essa última é, sem dúvida, a mais importante deles, chegando a ser responsável pela interrupção defi-
nitiva do tratamento em alguns casos. O mecanismo dessa dor permanece ainda não completamente
entendido. Tal fato faz do controle total da dor durante a terapia fotodinâmica um desafio ainda a ser
conquistado. Apesar disso, esta revisão apresenta algumas estratégias que podem ajudar os pacientes
a tolerar melhor a terapia fotodinâmica, além de relacionar os principais fatores ligados à dor descri-
tos na literatura. 
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INTRODUCTION 
Photodynamic therapy (PDT) is a therapeutic
method used for treatment of actinic keratoses,
Bowen’s disease, field cancerization, superficial basal
cell carcinoma, and thin nodular basal cell carcinoma.
It consists in the light activation of a photosensitizing
agent, which selectively accumulates in preneoplastic
and neoplastic tissues to generate reactive oxygen
intermediates. These intermediates irreversibly oxidi-
ze essential cellular components causing tissue dama-
ge and necrosis.1,2 It is extremely safe, effective, and
produces excellent cosmetic results with few adverse
effects.3 Pain, edema, erythema, pigmentation, and
pustules are among the main complications, with pain
being the most important one.4,5 
Pain assessment is extremely difficult due to
great interpersonal variation and the psychosocial fac-
tor inherent in it. During PDT, pain often manifests as
a burning sensation and usually peaks in the first
minutes of treatment, tending to stabilize or even
decrease by the end of it.6 The Visual Analogue Scale
(VAS) is the most widely used method to measure
pain, in which the patient indicates their pain intensi-
ty on a scale of zero to ten. Most studies agree that
about twenty percent of the patients undergoing PDT
rate pain over six on this scale, which is considered an
important level.5,7,8
The mechanism of action of pain in PDT has not
yet been elucidated. It is thought that nerve stimula-
tion plays a major role through receptors located at
the endings of myelinated A delta fibers and unmyeli-
nated C fibers. 9 Inflammation caused by cell necrosis
can also be decisive, particularly when pain persists
after the end of the sessions. Hyperthermia remains a
controversial factor. Orenstein et al. showed that,
during PDT, patients reported pain in the arm where
the photosensitizer had been applied and not in the
other one, where the photosensitizer had not been
applied, even using similar temperatures and radia-
tion.10 However, it is theorized that some pain recep-
tors would only be activated in the presence of hypert-
hermia combined with inflammation. The latter indu-
ced by photochemical reaction in the presence of the
photosensitizing agent.11
FACTORS RELATED TO PAIN IN PDT
In an attempt to identify cases with a greater
predisposition to pain, several factors were related to
it. These factors were type of photosensitizer, loca-
tion, extent and type of lesion, fluence, irradiance,
types of light source, number of sessions, and skin
phototypes.
TYPE OF PHOTOSENSITIZER (5-ALA VERSUS
METHYL ALA)
In most studies, MAL-PDT appears to be less
painful than ALA-PDT. 12-15 It is important to clarify
some differences in the mechanism of action of these
substances. ALA appears to be less selective for abnor-
mal cells than MAL, which may lead to a great accumu-
lation of protoporphyrin IX (PpIX), even in normal
cells.16,17 Wiegell et al. found no difference in pain bet-
ween MAL-PDT and ALA-PDT in the treatment of acne
and actinic keratoses when differences in the accumu-
lation of PpIX, measured by fluorescence, were cor-
rected.18 It is believed that ALA, unlike MAL, is trans-
ported into nerve endings by gamma-aminobutyric
acid receptors, which could precipitate painful stimu-
li (Table 1).14
LOCATION, TYPE AND EXTENT
Lesions in areas of rich innervation, such as the
head, hands, and perineum, seem to cause more pain,
as well as larger lesions. 5,7,19 Regarding the type of
lesion, actinic keratoses have been reported as more
painful than Bowen’s disease and basal cell carcino-
ma.5 Plaques of psoriasis are the ones that reach hig-
her levels of pain. 20,21 Acne can also produce signifi-
cant pain with both ALA and MAL-PDT, at levels higher
than those achieved when using only light irradiation.
22,23 Pain was measured during ALA-PDT to treat verru-
ca vulgaris, and not only high levels, but also long
time duration of an average of thirty-six hours was
observed. 24 Sandberg et al. noted that the erythema,
in addition to the extent, was significantly related to
pain during the treatment of actinic keratoses. In the
same study, erythema was also related to reduction of
the area with actinic keratosis and to cure rate.7
IRRADIANCE AND TOTAL DOSE OF LIGHT
(FLUENCE)
We must first distinguish between irradiance or
fluence rate, measured in MW/cm2, and fluence or
total dose, measured in J/cm2. Irradiance is inversely
proportional to the distance between the light source
and the treated area, and fluence corresponds to the
product of irradiance and time in seconds.3 Most stu-
dies show that the greater the fluences and irradian-
ces, the higher the levels of pain.8,20,25,26,27 Only one
study found no relationship between pain and irra-
diance. 28 In that study, irradiances of thirty to seventy-
five mW/cm2 were tested in the treatment of actinic
keratoses. Even so, both PpIX photobleaching and cli-
nical results were better under low irradiance.
LIGHT SOURCE AND LENGTH
The data regarding this topic are very inconsis-
tent. Incoherent light sources, continuous-wave laser
An Bras Dermatol. 2012;87(4):521-9.
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or pulsed light sources have already been used. The
ideal type of light for PDT should have the following
characteristics: high absorption by the photosensiti-
zer; high skin penetration; appropriate fluence and
duration; little pain, and good cosmetic result. 29 In
2007, Babilas et al. compared a pulsed light (VPL) with
a Light Emitting Diode (LED) and showed that pulsed
light was less painful than LED in MAL-PDT, even using
higher total fluence. This can be explained by the
short duration of the pulse, which was five millise-
conds, totaling 355 milliseconds at the end of the
treatment.30 The restricted time of exposure of the
photosensitizer to pulsed light may not be enough for
complete activation of the PpIX molecules, which
theoretically can decrease effectiveness with this light
source. Further comparative studies on the effective-
ness of PDT with pulsed light are needed for better
analysis of this topic. A trend toward less pain in PDT
with green light, in comparison with red light, has
been reported in the treatment of Bowen’s disease,
although the green light has presented reduced effec-
tiveness.31 Conventional MAL-PDT using LED was com-
pared with continuous activation of MAL by sunlight
for treatment of actinic keratoses on the scalp and
forehead.32 Continuous activation produced lower
levels of pain, possibly due to the fact that the sunlight
has lower irradiance than LED. This study deserves
some criticism for treating premalignant lesions with
potentially carcinogenic UV radiation, for the absence
of a specific spectrum of light, and because conti-
nuous activation of MAL interferes with appropriate
accumulation of the photosensitizer in the deeper
layers of the skin, thus preventing treatment of deeper
lesions. A more recent study compared LED (AKTLI-
TE) with a halogen lamp, which emits visible light plus
a filter for infrared light (HYDROSUN TYPE 505) and
found lower maximum levels of pain when using the
latter in the treatment of actinic keratoses.33 This diffe-
rence was only observed in the group that did not use
cold water spray during treatment.
FLUORESCENCE
Fluorescence can be easily observed with the
aid of a Wood’s lamp in routine medical practice.
Measurement of this fluorescence is, however, extre-
mely difficult, causing discrepancies among the stu-
dies on this topic. Fluorescence reflects the concentra-
tion of PpIX in the skin. The onset of pain during PDT
was related to the concentration of PpIX, measured
through fluorescence. This onset occurred with pho-
tobleaching of 50-60% of PpIX derived from ALA and
of 35-45% of PpIX derived from MAL. 34
Photobleaching of PpIX, in turn, depends on the
amount of singlet oxygen that will be formed and that
will be directly responsible for cell damage.35 Given
that the rate of oxygen consumption is proportional
to the product of concentration of PpIX (fluorescen-
ce) and irradiance, we may conclude that pain is rela-
ted to oxygen consumption, fluorescence and irra-
diance.27,34 Wiegell et al. also showed a direct relations-
hip between pain and fluorescence and irradiance in
a study that dealt with acne and actinic keratoses with
MAL-PDT. 26 Moreover, they concluded that there was
no relationship between pain and location or type of
lesions after correction of fluorescence. The results
found by the authors of this study corroborate that
higher fluorescence cause higher levels of pain.
NUMBER OF SESSIONS
There is one study showing that the second ses-
sion of PDT tends to be more painful than the first one
in most cases. The first session can serve as a predictor
of pain for the second session, since patients with sco-
res lower than five in the first session would have more
pain during the second session and vice versa. The rea-
son for this fact has not yet been clarified.36
SKIN PHOTOTYPES
A prospective study treated 141 lesions in 108
patients, including BCCs, Bowen’s disease and actinic
keratoses. 37 After correcting the factors associated
with high levels of pain, the only independent factor
associated with pain was skin phototypes 1 and 2. This
study did not take fluorescence of the lesions into
account and proposed as an explanation to this result
the fact that skin with higher concentrations of mela-
nin presents lower light penetration, resulting in less
formation of singlet oxygen and less tissue damage.
TABLE 1: Type of photosensitizer (5-ALA VERSUS METHYL ALA)
Study Diagnosis Results
(Number of patients)
Kasche et al, 2006 AK (69) ALA> MAL
Moloney and Collins, 2007 AK (16) ALA> MAL
Kuijpers et al, 2006 BCC (39) ALA = MAL
Wiegell et al, 2003 Photoexposed healthy skin (20) ALA> MAL
Wiegell and Wulf, 2006 Acne and AK (15) ALA = MAL
Arits et al, 2010 BCC, AK and BD (108) ALA = MAL
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PAIN MANAGEMENT DURING PHOTODYNAMIC
THERAPY
The perception of pain occurs due to nocicep-
tors located at the nerve endings of thin myelinated A
delta fibers and unmyelinated C fibers. The action
potential is generated when these nerve endings are
stimulated. 9 Propagation of this impulse may occur
directly through potassium ions or specific molecules
which accumulate during tissue damage, such as his-
tamine, bradykinin, serotonin, and prostaglandins
(substances found in mast cells, which can be degra-
nulated by activated porphyrin molecules).38
Several strategies for controlling pain during
PDT have been studied. Although some of them achie-
ve a reduction in levels of pain, none was completely
effective. The challenge of controlling pain during PDT
involves first a complete understanding of its real
mechanism, which remains unclear. The main met-
hods of pain management in PDT are described below.
THERMAL WATER
There is only one study in the literature on the
use of thermal water in photodynamic therapy. 39 This
study, sponsored by Avène, showed reduction in pain
from the third to the sixth day after PDT with Avène
thermal spring water and not with thermal water with
a high mineral content, when used every 4 hours after
each PDT session. Thermal spring water is thought to
have an inhibitory activity on mast cell degranulation
as well as an anti-inflammatory activity in vitro. 40 It is
known that intact axons may be directly activated by
molecules that accumulate during tissue damage and
that they may be the product of mast cell degranula-
tion.41 Thus, this inhibitory activity on mast cell degra-
nulation may help control pain. No study on the use
of thermal spring water during PDT session and with
no conflict of interest was found in the literature.
COLD AIR
Specific machines for cooling the skin with cold
air are increasingly common in medical practice and
can be really useful for pain management during PDT.
42 Cold air can reduce metabolism, which reduces the
effects of tissue damage. Cold air also stimulates A
delta nerve fibers, which activate the pain inhibitory
mechanism and raise its threshold. 43 The cold and
menthol receptor, also known as TRPM8, which pro-
motes analgesia in the early stages of inflammation, is
also responsible for pain reduction with cold air. 44
Regarding the influence of cold air on treatment effi-
cacy, the study that used forced cold air treated 26
patients with non-melanocytic skin cancer and found
no recurrence after a follow-up of 6 months.42 Another
study, however, showed decreased efficacy of PDT in
cases of actinic keratoses when cold water spray was
used, after a follow-up of  six months.33 In a recent
retrospective, observational, and controlled study,
Tyrrell et al. showed decreased bleaching of PpIX
when forced cold air was used for analgesia in relation
to the control group. Complete clinical cure after 3
months was also reduced. So, forced cold air equip-
ment must be used sparingly, although they are effec-
tive options for analgesia during PDT. 45
TOPICAL ANESTHETICS
No topical anesthetic showed any efficacy in
controlling pain during PDT. A double-blind, rando-
mized, controlled study with 14 patients with actinic
keratoses on the forehead showed no significant diffe-
rence in pain scores, regardless of the use of EMLA or
placebo. 46 In another study with 60 patients, EMLA
also showed no benefit.5 Another double-blind, rando-
mized, controlled study with 42 patients showed that
tetracaine gel 4% (Ametop) did not significantly redu-
ce pain during or after PDT for small lesions of super-
ficial BCC, Bowen’s disease, or actinic keratoses. 47
Morphine gel 0.3% also showed no benefit when used
in PDT for the treatment of BCC and actinic keratoses.
48 In a pilot study, after a pretreatment period of a
week with topical capsaiscin, for desensitization to
substance P, no pain relief during PDT was observed.
Furthermore, the use of capsaiscin also caused a bur-
ning sensation and pruritus in the sites where it was
applied.7 Lidocaine 3% for the management of pain in
PDT has been studied and has shown to be ineffecti-
ve.49 A possible explanation for the failure of topical
anesthetics in PDT is the fact that both ALA and MAL
have an acidic pH, while the majority of the topical
anesthetics have an alkaline pH, making their combi-
ned use incompatible.
INJECTABLE ANESTHETICS
Both infiltration anesthesia and nerve block
proved to be useful in the management of pain in
PDT. 50-52 The use of anesthetics without vasoconstric-
tor is recommended to allow adequate oxygen supply
in the area to be treated, thus ensuring the effective-
ness of PDT. Lidocaine, mepivacaine, ropivacaine and
tumescent anesthesia have already been used; all with
some degree of success in the management of pain.50-
52 Berking et al. used infiltration anesthesia with mepi-
vacaine in the treatment of actinic cheilitis and obser-
ved good pain tolerance in these cases. 50 Tumescent
anesthesia with ropivacaine, prilocaine, and epineph-
rine were used to treat actinic keratoses on the malar
region and produced lower levels of pain compared
to the isolated use of analgesics. In that study, howe-
ver, a local edema which lasted from about one to
three days was observed. 51 A study used nerve block
with mepivacaine and adrenaline in one half of the
An Bras Dermatol. 2012;87(4):521-9.
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face for the treatment of actinic keratoses on the
whole face. This study shows significantly reduced
levels of pain in the half part of the face where the
nerve block was applied, with a good level of patient
satisfaction.52 Serra-Guillen et al. compared cold air
and supraorbital and supratrochlear nerve block in
the treatment of actinic keratoses of the frontotempo-
ral region and showed that nerve block was more
effective than cold air in such cases.53
REDUCING IRRADIANCE
As discussed above, lower irradiances are rela-
ted to lower levels of pain, and irradiance is inversely
proportional to the distance between the light source
and the area to be treated. Using a LED red light sour-
ce (AKTLITE), Wiegell et al. showed that when the dis-
tance was increased from the 8cm recommended in
standard therapy to 25cm, irradiance fell by half.
Knowing that fluence or total dose corresponds to the
product of irradiance and time, exposure time must
be doubled to maintain the same total dose with half
of the irradiance. This way, it is possible to reduce irra-
diance in a practical and controlled manner, produ-
cing lower levels of pain without negatively affecting
treatment.26
INTERRUPTION OF SESSIONS
It has been shown that after interrupting PDT
for an interval of 3 minutes using cold water spray to
cool the area, a significant reduction in pain levels wit-
hout interfering with the rate of protoporphyrin IX
bleaching was observed. 54 The reduced pain levels
achieved during this interruption could be maintai-
ned if cold water spray continued to be used during
the second part of the session. In that study, follow-up
after the PDT sessions was not carried out, thus not
allowing for analysis of inflammation or of the rate of
cure after sessions.
CONCLUSION
Photodynamic therapy is a safe and effective
method of treatment that produces excellent cosmetic
results, when indicated properly. One of the main obs-
tacles to using this method is the pain caused by it. The
mechanism of this pain has not yet been completely
understood. This fact makes total pain management
during PDT a challenge to be conquered. Nevertheless,
this literature review presents some strategies that can
help patients better tolerate photodynamic therapy. It
also addresses the main factors related to pain during
PDT described in the literature. q
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1 - Knowledge of the dynamics of pain during photody-
namic therapy is essential for the physician to prepare
the patient and leave him/her more relaxed during the
sessions. Regarding pain in photodynamic therapy, it is
correct to state the following:
a) Pain starts at the time of application of the 
photosensitizer and increases until the end of the 
period of irradiation, when it subsides completely.
b) Pain tends to peak in the first minutes of 
irradiation and tends to decrease or stabilize by the 
end of the session. After the session, there may be 
lower levels of pain, which may last up to 36 hours.
c) Higher levels of pain tend to manifest after 
irradiation due to the intense necrosis and 
inflammatory reaction generated during PDT and 
may last up to 7 days.
d) Photodynamic therapy maintains pain levels 
constant and higher during irradiation. After the 
sessions, the pain tends to decrease, stopping within 
at most 24 hours.
2 - The mechanism of pain in PDT has not yet been fully
understood, but there are several important theories.
Regarding the mechanism of pain during PDT, it is cor-
rect to state the following:
a) Stimulation of specific nerve endings, 
inflammation, and hyperthermia must be involved.
b) Inflammation caused during PDT is minimal and, 
therefore, it does not influence the mechanism of 
pain.
c) A decisive factor in the mechanism of pain during 
PDT is local increased temperature, since pain 
increases proportionally to the increase in 
temperature, irrespective of other factors.
d) It is thought that nerve stimulation plays a major 
role through receptors located at the endings of 
myelinated C fibers and unmyelinated A delta fibers.
3 - Some studies have listed factors associated with pain
during PDT. Which of the following statements is true
regarding those factors?
a) According to most studies, ALA-PDT appears to be 
less painful than MAL-PDT, possibly because MAL, 
unlike ALA, is transported into nerve endings 
through gamma-aminobutyric receptors, which 
could precipitate painful stimuli.
b) Lesions in areas of rich innervation, such as the 
head, hands and perineum, seem to cause more 
pain, as well as larger lesions.
c) Basal cell carcinomas and Bowen's disease were 
reported as being more painful than actinic 
keratoses, which shows that the deeper the lesion is, 
the greater the likelihood to present pain.
d) Treatment of plaques of psoriasis with PDT shows 
irrelevant levels of pain. Thus, pain in these cases is 
not a significant adverse effect.
4 - The concepts of irradiance and fluorescence must be
well understood, since they are important factors rela-
ted to pain in PDT. It is correct to state the following
about these factors:
a) Fluence corresponds to the product of irradiance 
and time in seconds.
b) Irradiance is inversely proportional to the 
distance between the light source and the area treated.
c) Irradiance or fluence rate, measured in mW/cm2, 
and fluence or total dose, measured in J/cm2.
d) All of the above are correct.
5 - Various types of light sources have been studied in
photodynamic therapy. Which of the characteristics
below would make a light source ideal for PDT?
a) High absorption by the photosensitizer and low 
skin penetration.
b) High fluence and short duration.
c) Produce little pain and good cosmetic result.
d) Alternatives "a" and "c".
6 - Regarding the different sources of light during PDT,
it is correct to state the following:
a) Pulsed light seems to be a light source less painful 
than LED. However, the short exposure time of the 
photosensitizer can compromise treatment 
effectiveness.
b) Green light not only shows to be less painful than 
red light in the treatment of Bowen's disease, but 
also more effective.
c) Continuous activation of the photosensitizer by 
sunlight is more painful than conventional MAL-PDT.
d)  All of the statements above are true.
7 - A recent study has compared conventional MAL-PDT
to continuous activation of MAL by sunlight. This met-
hod is subject to some criticism. Among the options
below, choose the one that does not apply to conti-
nuous activation of MAL by sunlight:
a) It treats premalignant lesions with potentially 
carcinogenic UV radiation
b) It causes higher levels of pain than conventional 
MAL-PDT 
c) It prevents proper accumulation of the 
photosensitizer in the deeper layers of the epidermis
d) It does not have a specific spectrum of light
8 – Regarding factors related to pain in PDT, check the
wrong alternative below.
a) The higher fluorescence is, the higher the levels of 
pain experienced by patients tend to be.
b) The second PDT session tends to be less painful 
than the first one in most cases.
c) Irradiance is directly proportional to levels of pain 
during PDT.
d) Higher skin phototypes appear to present lower 
levels of pain due to less penetration of light as a 
result of higher concentration of melanin.
▲
QUESTIONS
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9 - One of the options for pain management during PDT
is the use of cold air. Regarding this option, it is correct
to state the following: 
a) Cold air can reduce metabolism, which reduces 
the effects of tissue damage.
b) Cold air stimulates A delta nerve fibers, which 
activate the inhibitory mechanism of pain and raise 
pain threshold.
c) The cold and menthol receptor, known as TRPM8, 
promotes analgesia in the early stages of inflammation.
d) All of the statements above are right.
10 - Regarding the use of topical anesthetics during
PDT, check the correct alternative below.
a) Topical anesthetics are an effective and easy-to-use 
alternative to control pain during PDT.
b) Both ALA and MAL have an alkaline pH, while 
most topical anesthetics have an acidic pH, making 
the combined use of these substances incompatible.
c) Most topical anesthetics do not interfere with the 
effectiveness of PDT, since they have a pH similar to 
that of the main photosensitizers.
d) Although they are effective in controlling pain, 
topical anesthetics should not be used because their 
pH is different from that of the photosensitizers.
11 – Regarding the use of injectable anesthetics during
PDT, check the correct alternative below.
a) It is recommended to use anesthetics with 
vasoconstrictor to minimize bleeding, which may 
diminish activation of PpIX.
b) Tumescent anesthesia proved to be an ineffective 
method of analgesia during PDT for preventing 
adequate penetration of light.
c) In the treatment of actinic keratoses of the 
frontotemporal region, nerve block was more 
effective than cold air in the management of pain. 
d) All of the statements above are true.
12 - One way to manage pain during PDT is to change
irradiance so that pain is relieved. Regarding this sub-
ject, check the correct alternative below.
a) One of the strategies to decrease pain levels 
during PDT is to decrease the distance between the 
light source and the irradiated surface.
b) The smaller the distance between the light source 
and the skin is, the lower the irradiance.
c) Increasing the distance between the light source 
and the skin lowers irradiation during PDT.
d) When irradiance is decreased, time of exposure 
should be decreased to maintain the same fluence.
13 - When evaluating pain during PDT, there are some
important factors to be considered. Which of the state-
ments below is true?
a) About 20% of the patients undergoing PDT rate 
pain levels above 8, which is considered a significant 
level of pain.
b) Pain during PDT is usually of a throbbing type and 
peaks at the end of the sessions.
c) The Visual Analogue Scale (VAS) is the most 
widely used method to measure pain during PDT 
sessions.
d) All of the statements above are true.
14 – Regarding Photodynamic Therapy, check the cor-
rect statement below: 
a) Actinic keratoses, Bowen's disease and nodular 
basal cell carcinomas with more than 2mm are 
excellent treatment options.
b) Pain is not usually an important factor among the 
adverse effects of photodynamic therapy.
c) It consists in the light activation of a photosensitizing
agent, which selectively accumulates in preneoplastic
and neoplastic tissues to produce reactive oxygen 
intermediates.
d) It consists in the light activation of a photosensitizing
agent, which accumulates in neoplastic and non-
neoplastic tissues to produce reactive oxygen 
intermediates.
15 - The main photosensitizing agents used in PDT are
aminolevulinic acid (ALA) and its methylester (MAL).
Regarding these agents, check the correct statement
below.
a) ALA is less selective for neoplastic and preneoplastic
cells than MAL.
b) ALA is more selective than MAL for neoplastic 
cells.
c) MAL, unlike ALA, is transported by gamma-
aminobutyric receptors into nerve endings, which 
may explain the higher levels of pain achieved with 
this substance.
d) There is no difference in accumulation of 
protoporphyrin IX (PpIX) between non-neoplastic 
and neoplastic cells with the use of both agents.
16 - Fluorescence can be an important factor in predic-
ting levels of pain during PDT sessions. Regarding this
subject, check the correct alternative below.
a) Fluorescence reflects the concentration of PpIX in 
the skin.
b) PpIX photobleaching depends on the amount of 
singlet oxygen that will be formed and that will be 
directly responsible for cell damage.
c) The rate of oxygen consumption is proportional 
to the product of concentration of PpIX and irradiance.
d) All of the statements above are true.
17 – It is sometimes necessary to interrupt a PDT ses-
sion upon the patient's request due to pain. Regarding
these interruptions, check the correct alternative
below.
a) If the session is interrupted, it should not be 
resumed due to the risk of reduced efficacy of PDT.
b) Once started, the session should not be 
interrupted under any circumstances.
c) Interruption of a PDT session for a few minutes is 
a strategy that can be used to help patients better 
tolerate the pain.
d) Interruption of the sessions does not help in 
controlling pain. In fact, it prolongs the pain 
reported by the patient.
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Information for all members:  The EMC-
D questionnaire is now available at the home-
page of the Brazilian Annals of Dermatology:
www.anaisdedermatologia.org.br. The deadline
for completing the questionnaire is 30 days
from the date of online publication.
1. C
2. D
3. D
4. D
5. B
6. C
7. B
8. A
9. B
10. C
11. D
12. D
13. C
14. A
15. D
16. D
17. C
18. B
19. D
20. D
Spitz Naevus and Reed Naevus 
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18 - In relation to the management of pain in photody-
namic therapy, it is correct to state the following:
a) PDT is a therapeutic method which is safe and 
effective and which produces minimal levels of pain, 
thus not requiring any resources for its management.
b) Although the mechanism of pain in PDT has been 
fully clarified, a completely effective method for the 
management of pain has not been found yet.
c) Although there is no completely effective method 
for the management of pain, some strategies are 
important to help patients better tolerate it.
d) Using topical anesthetics, pain management can 
be done simply, effectively, and without compromising
the effectiveness of PDT.
19 – In case a patient reports significant pain during a
PDT session, which attitude would be less suitable?
a) Interrupt the session for about 3 minutes, use 
cold water spray, and then try to resume irradiation.
b) Continue the session and combine it with the 
application of forced cold air.
c) Interrupt the session, apply topical anesthetic for 
30 minutes, and resume the session from the beginning.
d) Interrupt the session, use nerve block or infiltration
anesthesia, and continue the session.
20 - Which of the following lesions would probably pro-
duce greater levels of pain?
a) Bowen's disease on the arm with 3 mm in diameter.
b) Field cancerization with actinic keratoses on the 
whole forehead.
c) Superficial basal cell carcinoma on the leg.
d) Isolated hypertrophic actinic keratosis on the 
scalp.
